Keyword: Merck

At the annual meeting of the American College of Cardiology this week, a new analysis of Merck’s anacetrapib cast a shadow on DalCor’s hypothesis

Merck is extending its 2015 R&D pact with NGM Bio for a broad range of early-stage assets. It's also culling one therapy that didn't work out.

Cold Genesys is developing its lead asset as a single agent and in combination therapies and has taken it through phase 2 in bladder cancer.

Syndax’s entinostat missed its primary endpoints in two phase 1b/2 trials combining it with anti-PD-1 drugs from Genentech and Merck KGaA and Pfizer.

Merck's tender offer to acquire Immune Design ends a back-and-forth that transformed a potential licensing deal into an outright acquisition.

Ascletis has enticed a big pharma veteran to serve as its new head of R&D, with former MSD China global VP Zhengqing Li taking on the task.

Sellas Life Sciences is considering a number of “strategic options” to make sure it can fund development of a pair of cancer vaccines.

Merck is making a $300 million move to acquire Immune Design, developers of a midphase immunotherapy for non-Hodgkin’s lymphoma.

Aduro Biotech is throwing its resources behind assets that target the STING and APRIL pathways for the treatment of cancer.

A new screening system confirmed that an emerging class of cancer drugs called IAP antagonists have immune-boosting powers.